MedTrace Logo

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

NCT00337662 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 628

Last updated 2010-02-17

Study results available
· View outcomes & findings →

Summary

The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.

Conditions

  • Schizophrenia
  • Schizoaffective Disorder
  • Schizophreniform Disorder

Interventions

DRUG

olanzapine

10-20 milligrams (mg), oral, daily, 10 weeks.

DRUG

risperidone

2-6 mg, oral, daily, for 10 weeks.

DRUG

risperidone

2-6 mg, oral, daily, 10 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States
  • Argentina
  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00337662 on ClinicalTrials.gov